Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP01A
- Development stage
- Unknown
- Lead developer
- Samaritan Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SP01A is an oral HIV entry inhibitor developed by Samaritan Pharmaceuticals, Inc. for the treatment of HIV infection, particularly in treatment-experienced patients with antiretroviral resistance. The drug is a high-dose, stabilized oral formulation of procaine hydrochloride. SP01A operates through a novel mechanism of action by reducing intracellular cholesterol and corticosteroid biosynthesis, which prevents the organization of lipid rafts in cellular membranes. These lipid rafts are essential for the assembly and function of the HIV entry complex. By disrupting these membrane domains, SP01A blocks the fusion of the HIV receptor with both CCR5 and CXCR4 cellular co-receptors, thereby preventing the virus from entering host cells. The drug has undergone Phase II clinical trials as monotherapy and advanced to Phase III trials in Europe to evaluate its efficacy in treatment-experienced HIV-positive patients.
- Brand names
- AnticortVirucort
- Other names
- procaine hydrochloride
02
Targets
CCR5 (C-C chemokine receptor type 5)CXCR4 (C-X-C motif chemokine receptor 4)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on SP01A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP01A.